Glen Eagle Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Glen Eagle Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-175	Closed	-$12.5K	–	969
2021 Q4	$12.5K	Sell	175 -985	-85%	-$71.3K	﹤0.01%	584
2021 Q3	$86.8K	Hold	1,160	–	–	0.03%	291
2021 Q2	$89.7K	Hold	1,160	–	–	0.03%	281
2021 Q1	$85.6K	Hold	1,160	–	–	0.03%	270
2020 Q4	$81.4K	Hold	1,160	–	–	0.03%	257
2020 Q3	$65.7K	Hold	1,160	–	–	0.03%	271
2020 Q2	$67.6K	Hold	1,160	–	–	0.03%	250
2020 Q1	$53.9K	Hold	1,160	–	–	0.04%	253
2019 Q4	$64.8K	Hold	1,160	–	–	0.03%	281
2019 Q3	$54.9K	Hold	1,160	–	–	0.04%	273
2019 Q2	$62.1K	Buy	1,160 +100	+9%	+$5.19K	0.04%	255
2019 Q1	$58.5K	Buy	1,060 +175	+20%	+$9.25K	0.04%	254
2018 Q4	$41.7K	Hold	885	–	–	0.04%	262
2018 Q3	$52.6K	Hold	885	–	–	0.04%	254
2018 Q2	$48.4K	Buy	+885	New	+$45K	0.04%	258

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

AWA

Artemis Wealth Advisors New York $662M AUM 39.67% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

IFWM

Institute for Wealth Management Denver, Colorado $938M AUM 29.36% 1-Year Est. Return

Glen Eagle Advisors's PBE Position: Q1 2022 in Review

Glen Eagle Advisors sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2022, closing a stake of 175 shares — an estimated $12.5K sold.

Glen Eagle Advisors first reported a position in PBE in Q2 2018 and held it in 15 quarters. The position peaked at $89.7K in Q2 2021. 89 funds tracked by Wall St. Rank hold PBE as of Q1 2022.

Glen Eagle Advisors reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2022 after selling out during the quarter.
Glen Eagle Advisors sold 175 Invesco Biotechnology & Genome ETF shares in Q1 2022, an estimated $12.5K.
Glen Eagle Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q2 2018 and held it in 15 quarters.
Glen Eagle Advisors's Invesco Biotechnology & Genome ETF position peaked at $89.7K in Q2 2021.
89 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2022.

Based on Glen Eagle Advisors's 13F filing for Q1 2022, filed 13 Aug 2024.